Manufacture of plasmid DNA drug substance and drug product
Active Awarded Last action
- Contract number
- 75N91024F00002
- Awardee
-
Mriglobal UEI HKQHNFKNKL15
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,790,973
Award facts
- Opportunity
-
- MARTP1202402 Solicitation number
- Contract value 100% obligated
- $2,790,973.00 Current and potential, with all options
- Completion date 58% complete
- Current and potential, with all options
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Change Order | $1,266,044 | |
| Other Administrative Action | $0 | |
| Original award | $1,524,929 |
About this award
The National Cancer Institute awarded a delivery order valued at $2.79 million to Mriglobal (doing business as Midwest Research Institute) on September 25, 2024, for the manufacture of plasmid DNA drug substance and drug product. This contract, which is not subject to any small business set-aside designation, is structured as a cost-plus-no-fee arrangement with a completion date of April 30, 2028, and will be performed in Rockville, Maryland. Plasmid DNA represents an important class of therapeutic agents in cancer treatment and genetic medicine, and this manufacturing contract supports NCI's broader mission to advance cancer research and develop innovative treatment modalities.
Mriglobal is a Kansas City-based nonprofit research organization with extensive federal contracting experience across multiple agencies and a specialized focus on pharmaceutical manufacturing and drug development. The organization holds numerous significant indefinite delivery contracts, including substantial arrangements with the National Cancer Institute for research and repository services, and has demonstrated expertise in manufacturing clinical-grade pharmaceuticals and providing chemistry, manufacturing, and controls services across government and commercial sectors. This delivery order leverages Mriglobal's established capabilities in drug substance and product manufacturing to support NCI's therapeutic development initiatives.
Quick answers
Who was awarded contract 75N91024F00002?
75N91024F00002 was awarded to Mriglobal by National Cancer Institute (National Institutes of Health) on September 25, 2024.
How much is contract 75N91024F00002 worth?
The government has obligated $2,790,973 on 75N91024F00002.
Is contract 75N91024F00002 an order under another contract?
Yes. 75N91024F00002 is a delivery order under 75N91023D00010, an indefinite delivery contract.
Was contract 75N91024F00002 competed?
The extent of competition for 75N91024F00002 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award